INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Core Insights - Rezolute, Inc. is under investigation by Faruqi & Faruqi, LLP due to significant stock losses following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [2][3]. Group 1: Company Performance - Rezolute's shares experienced a dramatic decline on December 11, 2025, dropping from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decrease [3][4]. - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, with the highest dose showing non-significant reductions in hypoglycemia events compared to placebo [3]. Group 2: Legal and Investor Actions - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to contact them to discuss potential legal options [1]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2].